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ONE of the keys to understanding of the behavior of cancer in humans is
quantitation of the observations. The disease, even of a single site, is extremely
variable. One needs to know how to describe this viariability by efficient
statistics. Only then can one focus down on behavioral differences associated
with such things as treatment differences, histological differences in tumors or
the elusive host resistance. For efficient statistical description, and particularly
for efficient comparisons, one needs a distribution model that in a very few
parameters accurately and fully describes any set ofobservations. Most " error "
theory for instance supposes the " normal " distribution for random deviations.
There is substantial feeling that this destribution is not the basic one for many
biological events (Aitchison and Brown, 1963; Gaddum, 1945). In particular,
the distribution ofdeaths from a given disease plotted from onset are substantially
skew. To describe events such as these fully, other models are needed. For
cancer death times, two have been prominently advocated, the exponential
(radioactive decay is a paradigm) and the lognormal. The latter says that the
skewness is removed and normality achieved when death distribution is plotted
not against time but against the logarithm of time.
In 1948 and 1949, Boag published the major series of papers supporting the
lognormal model. He had first tested five groups of patients who had been
treated for particular types of cancer but had died of their disease. He showed
excellent agreement between the data and the lognormal model. Later he added
data on three series of untreated patients but was forced to point out that the
agreement was poorer. Tivey (1954) later applied the model to many series of
leukemia patients and also found that it fitted the data well (on the assumption
that all patients died or would die of their cancers).
Boag in his presentations advocated that the lognormal model be extended to
describe death times in total patient populations by making allowances both for
cures and for competing deaths from other causes. While he gave extensive
details on the appropriate calculations, hepresented noinformation as to howoften
his more complete treatment would fit real sets of data. Neither did Tivey's
work bear on the more general situation. Hence there does not seem to be actual
evidence that the lognormal model does in fact apply to typical clinical series.
Neither are there indications as to the kind of groups for which the model is not
applicable. Specifically there is no theory that would define its range.
In my own work I found as did Boag and Tivey that when one dealt with cases
selected because they were treatment failures, the lognormal model gave anJ. W. BERG
excellent description of the facts. I wished therefore to use it more widely but
felt unable to do so because of uncertainty as to whether extension to other types
ofpatient groupings was proper. Of course when one deals with a type of cancer
that kills rapidly and inevitably, one has the type of situation corresponding to
that studied by Boag. The more slowly cancers kill, however, the more deaths
from intercurrent disease may be expected. Then if one simply plots cancer
deaths, late deaths are under-represented because the population at risk has be-
come smaller. Boag probably had little effect from this because the cancers he
studied either killed quite rapidly or in the case of cervix cancer occurred in
younger patients for whom the competing risks would be less. Hence he could
well have been right in assuming he was dealing with a general, not a special,
distribution, but the assumption is still only that. (Cures introduce a second
complication; most users of the model separate them but some do not.) More-
over, there are many conceivable ways of choosing series besides picking only
cases treated for cure and it is of interest to see if the model fits these. Hence
before and while using the lognormal model in clinical-pathological studies,
further investigation of its appropriateness and range of applicability was under-
taken. More than 250 groups of patients drawn in many ways from 3 pools
totalling about 5000 patients have now been studied. This report summarizes
the key parts of that experience and hopefully answers some of the questions
posed above.
SOURCE OF THE SERIES
Three series are included in this survey. These were chosen first because all
difficult work on them had already been done. Clinical information ofpertinence,
pathological classification, and detailed follow-ups all had been obtained and
tabulated. In only one of the three series, that of the Memorial Hospital breast
cancer patients, had I participated at all with such organization of the data.
Hence, even more than is true in general, this report takes advantage of, depends
on, and embodies primarily the efforts of others.
The first series studied was a broad group. In 1958, the Cancer Registrars of
University College Hospital, London (UCH) published "The Collected Statistics
of Malignant Disease Seen at University College Hospital, London, During The
Period 1946-1950 ". This 631 page book gives a case by case summary of the
Registry's data with follow-up at least through 1955. Only a fairly small part
of the Registry was not included in the present tabulations. The largest mass
of data not tabulated was that for the last 3 of the 5 years of breast cancer cases.
Other studies had indicated the inadequacy of even 10 year survival information
on this relatively slow-moving cancer, a more adequately followed series was
available, and the first 2 years of the Registry cases alone gave a substantial
sample to work with. The second group of excluded cases were those types or
groups of cancer with less than 20 cancer deaths. The one large group of cases in
this category had cancer of the skin. Thirdly, to avoid confusion as to later
events and to keep this series comparable with the others, patients who had had
previous cancers other than skin cancer were passed over.
Finally, within the various sites, small groups of histologically aberrant
types were ignored: carcinoids of the gastro-intestinal tract and lung, Wilm's
tumor, minor salivary adenocarcinomas of oral cavity, adenocarcinomas of
esophagus, squamous carcinomas of stomach, and visceral sarcomas (including
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lymphomas) were the main exclusions. Exclusion was quite specific so those
cases without histological classification were tabulated. All subdivisions were
made on the basis ofthe given information; no terms were redefined or otherwise
altered. A total of 2245 cases were included in this part of the study and 174
survival curves were calculated therefrom.
The next group of cases was chosen to fill two needs: longer follow-ups of
breast cancer patients and more detailed breakdowns of a fairly uniform group of
cases. For this I had available the data on the series of 1458 1940-1944 breast
cancer cases from Memorial Hospital already intensively studied by Dr. Guy F.
Robbins and co-workers (e.g. Robbins and Berg, 1964). At the time of writing,
living patients in this series had been followed for an average of 20 years. All
patients hadentered the series because ofuniform treatment: radical mastectomy
undertaken with hope of cure. Thus treatment was not a variable and variation
in stage was limited, from small but definite invasive cancer on the one hand to
moderately advanced regional spread on the other. Among the items previously
recorded and rechecked on these patients were size of primary tumor and level of
axillary metastases ifpresent. A working expansion ofthe basic hospital classifi-
cation had been devised. It has prognostic validity within the series but the
present study may indicate some of its weaknesses.
Another special series of comparable size was studied and in more detail.
Through the courtesy ofDr. Basil Morson and Mr. H. J. R. Bussey, it was possible
to studytherecords onrectal carcinomapatients prepared by Mr. Bussey and Dr.
Cuthbert Dukes at St. Mark's Hospital, London. The object of the study was
exploitation of the lognormal death time distribution for pathological purposes.
This was successful and the full analysis of studies on 1435 patients is being
prepared. Here, the beginning of that investigation is described as it is relevant
to this survey. The cases had been seen between 1928 and 1952.
As in the breast series, only patients treated for cure by major resection are
included. Information available included stage, grade and location of the tumor
in the rectum as well as detailed follow-up information on the patients.
METHODS OF STUDY
The basic method of approaching the data was that outlined in a previous
paper (Berg, 1964). Cancer deaths were separated from deaths from other causes.
The latter were treated as nonspecific removals, equivalent to losses to observation
or patients currently living at an equal time after entering the series. Patients
developing new primary cancers were removed at that time to avoid confusion
as to which cancer killed. In this study, initial time for entry into the series was
time ofdiagnosis for the general surveys, time of definitive surgery for the special
rectal and breast cancer studies. Net cancer survival and mortality were calcu-
lated in almost the exact way outlined in the previous paper. The one change
made was to calculate the figures for each 3-month interval for the first 3 years,
and by 6-month intervals for the next two. This distributed the deaths more
evenly and also the data points along the log time scale discussed below.
When the survey of the University College Hospital cases was undertaken it
became clear that because of the substantial number of advanced, rapidly lethal
cancers, even 3-month intervals tended to blur the results. Hence an alternative
method of calculation was used in which the net cancer mortality was calculated
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for every point in time (here a month) at which a cancer death occurred. This
is the method described by Moore, Cramer and Knowles (1951) and their method
ofpoint plotting was adopted.
Once net cancer mortality to date has been calculated one must estimate the
final cure rate in the series: that fraction of the group who appear to have been
fully removed from risk ofdying ofthe cancer in question by the treatment given.
In the untreated groups from UCH the cure rate was zero. For the other UCH
cases the method of cancer mortality calculation permitted us to use the last
observed net survival rate as a cure rate. Original analyses were made on this
estimate. When indicated, adjustments were tried as described below. For
the detailed rectal cancer studies, a series of maximum-likelihood studies done on
the first part of the material according to the method of Boag (1949) indicated
that considering the cure rate to be 0.5% lower thanthe 15 or 20 year net survival
figure was a quite satisfactory approximation. For simplicity's sake, this esti-
mate was adapted for the rest of the rectal cancer study and for the Memorial
breast study as well. Most calculations were done by electronic computers.
The survival curves so obtained could be compared with any model. Interest
at this time was focused on the lognormal model but not on the general estimation
of distribution parameters. The wish was to see when the model fitted all the
data well and when there were systematic deviations. This aim led to adoption
ofa visual approach. Advantage was taken ofthe fact that a lognormal distribu-
tion will produce a straight line when the cumulative data are plotted on a log-
probability grid. The point values of net cancer mortality were translated to
per cent of total expected cancer mortality and plotted. If the points between
10 and 90% were formed close to a straight line, the lognormal model was assumed
to be applicable. When the line generated from the points was bent or broken,
e.g. Fig. 2, and so suggested a systematic deviation the model was felt not to
apply. Mere random-looking scatter as in Fig. 8 was ignored.
RESULTS
Tables I and II and Fig. 1-8 present the results ofthe survey ofthe University
College Hospital Registry Series. The first conclusion is that there most certainly
is not uniform lognormality in the material. Only half of the groups fitted the
model when the cases were divided only by general tumor site or type. At the
same time, there seemed a tendency for groups with more than fifty cancer deaths
to have death distributions closer to the lognormal (Fig. 1). This size emphasis
was surprising because it had not been seen when groups chosen as Boag had
chosen his were examined. Then lognormality was routinely obvious with as few
as 15 patients.
When there were irregularities, they could be complex as for leukemia (Fig. 2).
Most often, however, the non-lognormal curves were like that shown for pharynx,
oral, breast, and stomach cancers (Fig. 3, 4, 5, 7). This pattern of a single break
in the curve with the latter portion being steeper than the earlier is unlike the
classic curve for bimodal groups which were not found. These are doubly bent
lines like that of Fig. 10 though the break may be more in the middle of the line.
The singlybrokenlines usual here seem to result from excess deaths at the extremes
ofthe observation period. The line for pharyngeal cancer (Fig. 5) is not straight
because of a substantial number of deaths in the first month of observation.
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TABLE I.-Lognormality of Groups and Subgroups of Cancer Patients
from University College Hospital
Lognormality
-s- ^~~~~~.A
Tumor type Cases
Bladder carcinomas (1) . . . 96
Brain tumors . . . 75
Breast-all cases of carcinoma (2) 254
Stages I-III . . 189
Stages II-IV 180
Stages I-II . 131
Stages II-III . 115
Stages III-IV . 123
Stage I . 74
Stage II . . 57
Stage III . 58
Stage IV . . 65
Cervix uteri, squamous carcinoma . 117
Colon (excl. rectum) adenocarcinoma 111
Corpus uteri, adenocarcinoma . . 59
Esophagus, squamous carcinoma. . 55
Hodgkin's disease (1) . . 61
Kidney carcinoma (excl. Wilms's) 41
Hypernephromas . 30
Larynx, squamous carcinomas 69
Leukemias all (1) . . 49
Acute leukemia . . 11
Chronic leukemia . . 38
Chronic myelogenous 20
Chronic lymphocytic 18
Lung-carcinoma of . 446
Adenocarcinoma . 26
Anaplastic carcinomas . 122
Misc. classified carcinomas 16
Squamous carcinomas 90
Unclassified carcinomas 192
Lymphosarcomas (1) . 66
Mouth, squamous carcinomas 101
Tongue carcinoma 46
Other carcinomas 55
Nasal sinus . 21
Ovarian carcinoma . 77
Pancreatic carcinoma. . 32
Pharyngeal, epidermoid carcinoma 115
Hypopharyng3al carcinoma . 80
Naso and mesopharyngeal carcinoma 35
Prostate, adenocarcinoma 49
Rectal adenocarcinoma 117
Sarcomas, bone and soft tissue . 58
Bone sarcomas . 19
Soft tissue sarcomas 39
Stomach, adenocarcinoma of 149
Testis, cancer of . 35
Tumor All
deaths cases
. 73 (+)
. 63 (+)
. 162 (+)
. 103 +
. 127 +
. 68
. 68 +
. 94 . +
. 35
. 33 +
. 35
. 59 +
. 71 +
. 95
. 26 -
. 47
. 61 -
. 34
. 25 +
. 34
. 46 -
. 11
. 35
. 20 -
. 15 -
. 433 +
. 26 +
. 118
. 16 +
. 82 +
. 191 +
. 48 +
. 57
. 35
. 22 +
. 17 +
59 . ?
. 31
. 101
. 70 -
. 31
. 39
. 75
. 38 . -
. 15 . +
. 23 . -
138 (+)
. 17
Treatment subgroup*
No Rx Pall
pall Rx No Rx Pall
- (+) + -
(+)
+
+
+
+
(+)
±+
+
+
+
+ _
+ -
+
_ +
(1) Subgrouping do not apply
(2) No untreated cases so total same as pall and Rx.
- Non lognormal
+ Lognormal
(+) Lognormal to date when cure rate adjusted downward.
(blank) Does not apply or less than 15 cancer deaths.
* No Rx No treatment
Pall-Palliation only
Rx Radical treatment
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TABLE II.-Lognormalityof University College Hospital Cases "Radically" Treated
(All Groups with 18 or more Cancer Deaths)
(3)
(2) Final (4) Lognormality
(1) Number actuarial Adjusted _
Number cancer salvage cure rate* Total
Tumor type of cases deaths (%) (%) group Subgroups
Carcinoma of breast 192 . 108 . 38 21 +
Stages I-III . 171 91 . 40 35 +
Stages II-IV . 124 . 76 31 28 +
Stages I-II . 123 63 . 42 . 31 +
Stages II-III 103 59 33 . +
Stages III-IV . 69 . 45 29
StageI . . . . 68 32 49
StageII. . . 55 . 31 32 +
Stage I. . . 48 28 34
StageIV. . 21 17 . 17 . 0 . . +
Carcinoma of lung 78 56 7 . +
Squamous carcinoma. 37 25 . 24
Carcinoma ofcervix uteri 104 58 40 . +
Carcinoma of pharynx . 54 . 41 . 13 . +
Carcinoma of hypopharynx 40 . 31 . 12 . +
Carcinoma of rectum . . 62 . 31 42
Carcinoma of stomach 33 . 25 24 . 0 +
Sarcomas . . . 42 . 22 45
Carcinoma of mouth 63 . 20 60 . . +
Carcinoma corpus uteri. . 51 . 18 . 62 .
* If not equal to Col. 3
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FIG. 1.-Lognormal curve. UCH lung cancer cases.
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FIG. 2. Non-lognormal curve. UCH leukemia cases. Acute and chronic cases combined.
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Fio. 3.-Non-lognormal curve. UCH breast cancer cases, with only 120 month follow-up.
Compare Fig. 9 with 20 year data.
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FIG. 5.-Non-lognormal curve. UCH pharynx carcinoma cases. Cf. Fig. 6.DISTRIBUTION OF CANCER DEATHS IN TIME
These are found in the " not treated " and " palliated " groups. When cases
" radically " treated are considered alone the data becomes lognormal between
5% and 95% of the deaths (Fig. 6).
A similar effect can be caused by unrealistically assuming that the last observed
patient death from cancer corresponds to the last 2 or 3% ofdeaths in the under-
lying sampled population. The effect of this is illustrated for breast cancer
data (Fig. 3) since the true distribution of deaths is shown in the second series
(Fig. 9). One hundred months ofobservation simply was not enough to complete
the story for breast cancer though it almost surely is adequate for more rapidly
moving cancers such as lung. With this possibility in mind, all series that were
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FIG. 6.-UCH pharynx cancer cases; the subgroup treated for cure. Cf. Fig. 5.
not lognormal were retested on the assumption that all cancer deaths possible had
not yet occurred. Those that could become lognormal with thisassumption are so
indicated on the tables. It must be emphasized that such " correction " is only
a guess when it has not been checked by longer-term work. The prime value
of such adjustment is to purify the list of groups not considered lognormal.
They are the ones that no change in observed cure rates could bring into cor-
respondence with the model.
A few of the categories had been taken knowingly more broadly than seemed
reasonable, the lumping of all leukemias together and the combining of soft
tissue and bone sarcomas being the most flagrant examples. This of course
could have been amajor cause ofthenegative results. Hence, wheneversmallness
ofgroups or unsuitability ofcategories did not prevent it, subgroups of cases were
examined separately. The results have been included in the tables. In cases of
oral-pharyngeal cancer, the results of increased precision seemed paradoxical.
Separating tongue cancer cases from the rest of the oral cavity cancer cases did
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not improve the lognormality ofthe former but did bring the residual mixture into
closer correspondence with the model (Fig. 7, 8). Similarly, separating the
hypopharyngeal cancer cases from the rest of the pharynx cancer cases did
nothing for the former data but did improve the fit ofthe residual mixture.
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FIG. 7.-Non-lognormal curve. UCH intra-oral epidermoid carcinoma cases. Cf. Fig. 8.
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FIG. 8. Rectification of data plot by removal of tongue cancer cases from group ofFig. 7.
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The only situation in which site separation followed expectation was in the
kidney cases. Separating cases with hypernephromas from the few with pelvic
tumors brought lognormality to the former. Nothing was gained by separating
the soft tissue sarcoma cases from bone tumor cases; perhaps nothing should
have been expected since both groups still were markedly heterogeneous though
with too few cases to permit further division.
Separation of the leukemia cases into 3 groups, acute, chronic myelogenous,
and chronic lymphatic, brought the data no closer to the model. The work of
Tivey (1954) is so convincing in its demonstration oflognormality for this disease
properly subdivided that the UCH material must be considered aberrant here.
Subdivision of lung cancers by histological type gained little. Rather there were
unexpected departures from lognormality. The same increase in nonlognormality
was seen in the permutations and combinations of breast cancer cases considered
by stage. Some subgroups retained the parent lognormality, others obviously
lost it.
The next thought concerning the nonlognormal groups was that the Registry
series was more heterogeneous than those previously studied. Any and all
patients were entered, regardless of treatment rather than because of a specific
form. At the same time, the distribution of cases between those so advanced as
to permit no serious attempt at cure or even palliation and those seen early would
seem to be as much a characteristic of the Hospital and the time as of the nature
ofthe disease process. To this extent, the distribution of cases is a particular one
and no prior distribution rationally can be predicated.
The obvious step then was to make the groups more uniform by dividing them
according to the general amount of treatment. As Table I shows, removing
" radically " treated cases to approximate a series of failures did not increasethe
lognormality of the data appreciably. Trimming the other end of the spectrum
by eliminating nontreated cases improved the lognormality in 3 groups but
destroyed it in one large group where it might have existed, namely stomach
cancer. No movement towards lognormality was seen when the " nontreated "
or " palliated " cases wereexamined separately. The only suggestiveimprovement
by this finer focusing appeared when the patients treated " radically " were looked
at alone (Table II). Then for the first time oral and pharyngeal cancers showed
the lognormality Boag had seen. Also the 2 largest groups which did not fit
were rectal cancers and " sarcomas ". The latter group is obviously quite
heterogeneous while the rectal cancer cases only reproduced a finding from other
series as noted below.
The impression from this portion of the study was that lognormality was not
always seen in unselected material; infact it described the death time distribution
well only about half the time. It may be something of a limiting distribution
however since it seemed to be approached as group size increased. When one
considered only cases treated for cure, it did seem to be a more applicable
model, and the size requirements seemed to drop substantially. The other
two series studied go more deeply into this aspect. Considering only patients
treated for cure, do subgroups of cases fit the model more often or in a more
rational way?
Table III presents the results of the intensive study of breast cancer patients
both as a whole and after various types of subdivision of cases according to factors
known to influence prognosis. In general, there was reasonable correspondence
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TABLE III.-Lognormality of Memorial Hospital Breast Cancer Cases Patients
TreatedbyRadical Mastectomy 1940-1943 (All Groups with 18 or more Cancer
Deaths)
No. of Cancer Log
patients deaths normal? Adj. Size,
1-1 -9 cm. . . . . . . . . 247 88 + +
2-2*9cm. 392 170 + +
33 9 cm. 303 180 +
4-49 cm. . . 164 101 . +
55 9 cm. . 97 . 66 . +
6-9 9 cm. . . 121 . 84 . + . +
10 cm. and over . 25 . 21 +
Multiple . . . . . . 31 . 20 +
Axillary1 lCvels of metastase8
None . . . . . 578 138 + +
194 . 104
"2 . . . 118 . 74 . +
3 . . . . . 317 . 296 +
Histologic type
Grade III-IV duct . . . 696 . 428 +
Grade I-II duct 246 . 98 +
Lobular 125 . 71 +
Medullary . . 62 21
Grade III-IV duct with plasma cell infiltrate . 135 . 63
Age
30-39 years . . 213 . 122 +
40-49 years . . 489 . 237 +
50-S59 years . 399 . 225 +
60-69 years 271 . 134
70 plus years . 66 . 24
between data and model. Fig. 9 illustrates this for the total group. This
confirmed previous observations and justified the extrapolation on UCH cases.
Subcategories seemed equally well behaved. The only method of division
yielding more than a rare definite exception was that by histological type. These
groupings were the only subjective ones so that the failure of fit seems more
likely an indictment of the detailed schema for classification than failure of the
lognormal model.
The last series of St. Mark's rectal cancer cases was particularly suited to
examine the question of where the fault lies when data and model do not match.
The original observation was a duplication of an equivalent Memorial Hospital
clinical series. Like the UCH group, the overall rectal series was nonlognormal
(Fig. 10). While Dukes' C cases (and in the Memorial series, Dukes' A cases
though these could not be tested in the St. Mark's equivalent since too few died)
were lognormal, Dukes' B cases were not (Table IV, Section A). Following this
further, discrepancy proved to be a time-dependent finding since it was not seen
in the later years. It was not found in cases with higher tumors or with low
grade cancers (Section B of Table IV). Exploring this further two factors were
found to be acting. One was a now obsolete operation. When this was aban-
doned, a second late group of deaths disappared and most of Dukes' B subgroupsDISTRIBUTION OF CANCER DEATHS IN TIME
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TABLE IV.-Lognormality of Groups of Rectal Cancer Cases from
St. Mark's Hospital, London
Cancer
Cases deaths Lognormality
A. Survey of 1932--1937 cases divided by stage
Dukes' stage
B 84 21
C 138 90 +
C1 70 35 +
C2 65 53 +
C average grade 64 35 +
C anaplastic 67 52 +
B. Survey of Dukes' B cases
5-Year period
1928-1932 . 71 28
1933-1937 84 21
1938-1942 103 33 +
1943-1947 173 47 +
1948-1952 221 65 +
Location
Low rectuin 221 64
Mid rectum 197 71
Upper rectumrn 234 59 . +
Histological grade
Low 148 39 +
Average 442 127
Anaplastic 62 28
became lognormal. The other factor was less apparent in large groupings since
it was related to anaplasia and few anaplastic tumors were of ]Dukes' B stage.
When the anaplastic tumors were looked at alone, a biphasic pattern was seen.
This was followed further, found to persist in other stages, and finally the sub-
group of tumors responsible for the biphasic grouping of death times was identi-
fied. These were particularly lethal cancers, fully deserving of separate identi-
fication since they killed not only twice as fast but left only about half as many
5 year survivors as the cancers they had been mixed with.
Of about 100 subgroups studied in the rectal series, " unexplained " non-
lognormality was found only once. Almost all of the groups that had non-
lognormal distributions had them for a discoverable reason. Hence in general,
the lognormal model seemed as applicable to treated rectal cancer cases as to the
breast series and the other studied of patients treated for cure. This being the
case, the instances in which the data did not fit the model were those most
useful in case study.
DISCUSSION
Probably the first question raised by this study is the validity of the visual
approach to a decision. As authorities favoring the approach, one may cite
Moore, et al. (1951) and Bliss (1937). The calculation of best fitting lines seems
an attractive alternative at first glance but not so at second. Such calculation
used a large amount of computer time; the results rarely proved more than
trivially better than the eye plots; but most important, when there was a
systematic deviation, the calculated line would tend to obscure it rather than
point it up. No method has been suggested whereby one through computationDISTRIBUTION OF CANCER DEATHS IN TIME
could, with assurance, recognize systematic as opposed to non-systematic varia-
tions.
Accepting the present method then, the lognormal model often seemed
applicable and a good description of groups of cancer cases with homogeneous
treatment. To this degree the results ofthis survey support Boag's extrapolation.
A simple way to try to achieve treatment uniformity is to consider only patients
treated for cure. When no treatment is very successful, the model may also fit
as it did the totality oflung cancer cases. When there are mixtures ofeffectively
and ineffectively palliated cases, the model usually did not seem applicable,
particularly with particular distributions of patients in these two groups. Insofar
as the results may have in this way reflected a situation local to University
College Hospital, they call for confirmation.
It would also be interesting to have longer-followed material for other types of
cancerbesides breastandrectal carcinoma since onlywithfollow-uppast thepredic-
ted 99% mortality time can one have real confidence in correspondence with the
model. With earlier cut-off, a subsequent flurry of deaths could destroy what
was till then an excellent fit. The lognormal model seems particularly sensitive
to this situation-almost any assumption about cures still leads to a plot of death
times that is linear in the first half of the data.
One example now exists that confirms the UCH observations for Hodgkin's
disease. Neither there nor in the preliminary Memorial survey did the data fit
the model. Hansen (1964) recently published an Australian series with survival
curve data on which a lognormal study could be done. There again his group as
a whole proved not to fit the model. However, when one removed the two small
but very slowly lethal cases, those with " paragranulomas " and the newly-
described " nodular sclerosing " variety, the remaining cases were in fact log-
normally distributed. One thereby has added incentive to look closely at other
groups that fail to fit the model to see if they too are composed of subgroups of
importantly different survival.
Because ofthis property, a point taken for granted earlier in this presentation,
probably should be spelled out to counteract misuse of this model. The model
clearly applied to treated rectal and breast cancers only on the assumption that
there were cures and only when the cured fraction of patients was separated off.
It is true for most other cancers as well if cures appear to be achieved clinically.
Stomach cancer cases from the UCH series were the most prominent exception
I have encountered to this. If one feels that the no-cure situation applies, at
least this should be specified so that the rationality of the assumption may be
considered rather than just using say a probit curve to describe a total group of
patients without adjustment.
The question of other models seems of more theoretical than practical im-
portance. An exponential model has received the most attention (Berkson and
Gage, 1952; Koldin, 1961) but its primary justification is simplicity. The
Weibull model (Lieblein and Zelen, 1956) seems the most interesting alternative
coming from industrial life testing which may or may not be analogous to survival
with cancer. At the moment, none of the models follows from major established
assumptions about cancer behavior. They must stand or fall on their merits, on
how wellthey do theirjob. Their first job is to describe the series. The lognormal
exponential and Weibull models all produced about the same figures for median
survival time and cure rate in equivalent series tested at the time of writing.
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The distribution of cases around this time also was not much different. In the
first few months of a series, often no model fitted too well, though the exponential
tended to be particularly poor as long noted.
We have yet too little data about truly late cancer behavior though this may
well be an even more crucial region for choosing one model over another as far
as adequacy of description goes.
Though we have some information on adequacy of description, we have as yet
none on two two points that are of some importance in choosing a model: power
in predicting final values of such figures as cure rates from incomplete data and
power in making comparisons between groups of patients. In the first problem,
a model is vital, in the second, important as an improvement over nonparametric
comparisons. There is oneplace wherethelognormal modelhas shownadvantages
yet to be claimed for the other models. Heterogeneous groups often are marked
by systematic deviations from the model that are easy to see. With the other
models the picture tends to be merely accentuation of expected deviations and
recognition of significant cases has not seemed simple.
Another unexamined problem is the question of the most desirable initial
point of time. Here, dates of diagnosis or first treatment were used. Time
could also be computed from beginning ofsymptoms though this poses difficulties.
It is a subjective date, known to be inaccurate. It may relate not to the cancer
but to a precancerous state. Use of it means a loss of the cohort structure one
has in taking all patients eligible in a given time interval, and it produces
complications when there is a cured fraction (chance of cure often is correlated
with symptom time). Still it might serve to bring the data closer to Bliss'
original use in describing death times. He measured time fromthe administration
of a toxin and so had a real time zero not possible here. The deaths still were
lognormally distributed. Hopefully theory of cancer behavior will account for
the agreement between his observations and the present ones.
CONCLUSIONS
The degree of correspondence between lognormal models and actual death
time data has been the subject of 3 complementary surveys involving about 250
partly overlapping groups of cancer patients. The requirement for the model to
be applicable seems to be a continuity of patient material. Here treatment was
the most obvious factor to be controlled within limits; unless there was treatment
for cure or no effective treatment at all, the model tended to fail. As an often
good description of cancer death times, the model can serve to summarize data
and simplify comparisons. In addition and most important for pathological
studies, non-conformity, when unexpected, usually can be explained by patient or
cancer differences that are thereby brought to light.
Most of this work was done while the author as recipient of an Alfred P.
Sloan Foundation Award in Cancer Research, 1963, was with the Statistical
Research Unit of the Medical Research Council, Dr. Richard Doll, Director.
Much of the computation was performed on their Elliott 803 computer. Other
work was done on another 803 at the Elliott Medical Automation Center, and on
the CDC 160A of the Medical Physics Department, Memorial Hospital (USPHS
Grant CA 06102). The author wishes to thank the many people who assisted him
at these instaUations.
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